期刊
JOURNAL OF PERINATOLOGY
卷 42, 期 1, 页码 31-36出版社
SPRINGERNATURE
DOI: 10.1038/s41372-021-01261-w
关键词
-
资金
- Eunice Kennedy Shriver National Institute of Child Health and Human Development [HHSN275201000003I]
The study found that sildenafil was well tolerated by premature infants, but careful attention is needed to drug administration times and flush rates to prevent infusion-related hypotension associated with faster infusions of IV sildenafil.
Objective To characterize the safety of sildenafil in premature infants. Study design A phase I, open-label trial of sildenafil in premature infants receiving sildenafil per usual clinical care (cohort 1) or receiving a single IV dose of sildenafil (cohort 2). Safety was evaluated based on adverse events (AEs), transaminase levels, and mean arterial pressure monitoring. Results Twenty-four infants in cohort 1 (n = 25) received enteral sildenafil. In cohort 2, infants received a single IV sildenafil dose of 0.25 mg/kg (n = 7) or 0.125 mg/kg (n = 2). In cohort 2, there was one serious AE related to study drug involving hypotension associated with a faster infusion rate than specified by the protocol. There were no AEs related to elevated transaminases. Conclusion Sildenafil was well tolerated by the study population. Drug administration times and flush rates require careful attention to prevent infusion-related hypotension associated with faster infusions of IV sildenafil in premature infants.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据